. The increased cardiac hypertrophy and heart functions in vivo is not heart size was already detectable in newborn mckCREknown. PTEN ⌬/⌬ mice (not shown). Histologically, the increase We investigated the role of the PI3K-PTEN signaling in heart size was observed throughout the heart (Figure pathway in cardiac hypertrophy by studying PTEN-heart 1D). Interestingly, cardiac hypertrophy did not result in muscle specific mutant mice, p110␥
, dominant-negafibrotic or structural changes in myocyte organization tive p110␣ transgenic mice, and double-mutant mice.
( Figure 1D ) or perturbations in cardiomyocyte cell death We show that two independent PI3K signaling pathways (not shown) even at 1 year of age indicating that loss exist in cardiomyocytes that can be genetically uncouof PTEN does not result in cardiac decompensation or pled. While the tyrosine kinase-receptor p110␣-PTEN dilated cardiomyopathy. pathway is a critical regulator of cardiac cell size, the To further analyze the cardiac hypertrophy in GPCR-linked PI3K␥-PTEN signaling pathway modulates PTEN-deficient hearts, cardiomyocytes were isolated heart muscle contractility.
from adult mice to assess the individual cell size. Loss of PTEN resulted in a marked increase in both the length and width of cardiomyocytes as compared to controls Results ( Figure 2B ). The length-to-width ratio was unchanged in these cells indicating that the cell size change was Generation of Cardiac Muscle Specific PTEN Knockout Mice similar to that observed in physiologic hypertrophy (Hunter and Chien, 1999). Pathological cardiac hypertroInactivation of PTEN in all cells results in early embryonic lethality between day 6.5 to 9.5 (Suzuki et al., 1998; phy is characterized by a prototypical change in gene expression patterns such as increased ANF, ␤MyHC, Di Cristofano et al., 1998). We therefore used a tissue BNP, and skeletal-actin expression, and a decrease in ␣MyHC (Hunter and Chien, 1999). However, no significant alterations in the expression profile of these hypertrophic genes were observed with the exception of an increase in ␤MyHC ( Figures 2C and 2D) . Thus, loss of PTEN in the myocardium induces hypertrophy without the typical pathological changes in the gene expression profiles or cardiac decompensation.
Activation of PI3K Signaling in PTEN-Deficient Hearts
Since PTEN antagonizes the action of PI3K, we analyzed whether the loss of PTEN in the hearts results in the activation of downstream targets of PI3K signaling (Downward, 1998). Loss of PTEN resulted in a significant increase in the basal phosphorylation state of AKT/PKB ( Figures 2E and 2F ). In addition, we found an increase in the phosphorylation of GSK3␤ and p70
S6K , both downstream targets of PI3K signaling (Figures 2E and 2F).
No apparent changes in the basal activation of ERK1/ ERK2 were observed between the mutant mckCRE-PTEN ⌬/⌬ mice and their mckCRE-PTEN ⌬/ϩ and PTEN ϩ/ϩ littermates ( Figures 2E and 2F ). These data establish that loss of PTEN in cardiomyocytes results in increased PI3K signaling leading to activation and phosphorylation of multiple PI3K target molecules.
Loss of PTEN in the Heart Results in Decreased Cardiac Contractility
To further characterize the role of PTEN in mutant mckCRE-PTEN ⌬/⌬ mice, we analyzed the hearts using echocardiography. Consistent with the physiological cardiac hypertrophy, echocardiography of PTEN-deficient hearts revealed an increase in the anterior wall thickness and an increase of the left ventricle mass (LVM) at all ages analyzed ( Figure 3A and Table 1) . Moreover, the change in end diastolic dimension of the left ventricle (LVEDD) reflected this overall enlargement of PTEN-deficient heart. No difference in heart rate was detected in the PTEN-deficient hearts (Table 1) . Surprisingly, assessment of cardiac function by echocardiography revealed that mutant mckCRE-PTEN ⌬/⌬ mice exhibited a dramatic reduction in cardiac contractility characterized by decreased fractional shortening (FS), decreased velocity of circumferential fiber shortening (Vcfc), and reduced peak aortic outflow velocity (PAV; Figures 3B, 3C , and Table 1 ). To confirm the echocardiographic alterations, functional invasive hemodynamic measurements were performed. Our hemodynamic measurements showed that both dP/dT-max and dP/dT-min were markedly reduced in the PTEN mutant mice (Table 1) , again indicating severe impairment of in contractility at 10 weeks, there was no further de-(B) Western blot analysis for p110␣, p110␤, p110␥, and p85 exprescrease in the function of the PTEN-deficient hearts anasion levels in total heart lysates from 2 representative mckCRElyzed at 12 months of age (Table 1 ). In addition, there was PTEN ⌬/ϩ and two mckCRE-PTEN ⌬/⌬ mice.
no evidence of dilation, wall thinning, or tissue fibrosis in (C) Representative heart sizes of 10-week-old mckCRE-PTEN ⌬/ϩ and older animals ( Figure 1D , Table 1 ). These data show that The decrease in cardiac contractility found in the PTEN mutant hearts suggested that increased PI3K signaling serves not only to increase cell size in the heart but to esized that the decreased heart function in PTEN mutant mice is mediated by PI3K␥. We observed p110␥ protein also suppress basal heart function. Neither the p110␣ dominant-negative nor p110␣ constitutively active heart expression in total heart extracts of mice ( Figure 1B ) and in isolated cardiomyocytes ( Figure 3D ). Loss of p110␥ specific transgenic animals showed any alteration in heart function (Shioi et al., 2000) suggesting that the expression does not alter the expression levels of p85, p110␣, and p110␤ ( Figure 3E ). Moreover, p85 associated effect on contractility is mediated by PI3K isoforms other than PI3K␣. Since several GPCR signaling pathways, PI3K activity in cardiomyocytes was comparable between p110␥ Ϫ/Ϫ and wild-type littermates using in vitro including adrenergic receptors (Rockman et al., 2002) , are important mediators of cardiac function, we hypothlipid kinase assays (not shown). There was also no ap- Table 1 ). Hemodynamic measurements confirmed contractility persisted (Vcfc: 8.65 Ϯ 0.2 in wild-type versus 10.86 Ϯ 0.17 in p110␥ Ϫ/Ϫ mice; n ϭ 6; p Ͻ 0.01) the increased heart contractility in p110␥ Ϫ/Ϫ mice ( Table  1) . Telemetry analysis of blood pressure in conscious and there was no evidence of cardiac hypertrophy or increased myocardial fibrosis in 1-year-old mice (not mice revealed normal blood pressure in p110␥ Ϫ/Ϫ mice (not shown). In addition, plasma epinephrine and norepishown). Thus, loss of PI3K␥ results in a marked increase in cardiac contractility. nephrin levels were not altered in p110␥ Ϫ/Ϫ mice compared to controls [norepinephrin (59.63 Ϯ 9.99 in wildtype (n ϭ 6) versus 61.28 Ϯ 8.82 in p110␥ Ϫ/Ϫ mice (n ϭ PI3K␥ Mediates Reduction of Heart Function in PTEN-Deficient Hearts 6), and epinephrin (4.65 Ϯ 0.80 in wild-type (n ϭ 6) versus 4.28 Ϯ 0.55 in p110␥ Ϫ/Ϫ mice (n ϭ 6)]. The alterations in heart muscle contractility in p110␥Ϫ and PTEN mutant hearts were exactly opposite, that To determine if there are any long-term effects of this increase in cardiac function in p110␥ deficient mice, we is loss of PTEN resulted in decreased heart functions whereas loss of p110␥ leads to a marked enhancement analyzed heart function by echocardiography in 1-yearold mice. Similar to that observed in younger mice, there in cardiac contractility. To determine if the role of PTEN in regulating cell size and heart function could be genetiremained an increase in cardiac contractility [fractional cally uncoupled, we generated mice deficient for both p110␥ and PTEN in the heart. Hearts from mckCRE-PTEN ⌬/⌬ p110␥ Ϫ/Ϫ double-mutant mice were significantly enlarged as compared to wild-type and p110␥ Ϫ/Ϫ mutant mice ( Figure 3A , Table 1 ). The extent of cardiac hypertrophy in mckCRE-PTEN ⌬/⌬ p110␥ Ϫ/Ϫ doublemutant mice was similar to that observed for hearts from mckCRE-PTEN ⌬/⌬ single mutants ( Figure 3A) . Histologically, hearts from mckCRE-PTEN ⌬/⌬ p110␥ Ϫ/Ϫ doublemutant mice were also similar to that of mckCRE-PTEN ⌬/⌬ single mutant mice. Importantly, similar to PTEN-deficient hearts, AKT/PKB was hyperphosphorylated in the hearts of mckCRE-PTEN ⌬/⌬ p110␥ Ϫ/Ϫ doublemutant mice ( Figure 3G ). Thus, loss of PI3K␥ in PTENdeficient hearts has no affect on the increased AKT/ PKB phosphorylation and does not rescue the cardiac hypertrophy phenotype.
However, unlike PTEN-deficient hearts, mckCRE-PTEN ⌬/⌬ p110␥ Ϫ/Ϫ double-mutant hearts were found to be hypercontractile, as assessed by increased fractional shortening (FS), Vcfc, and peak aortic outflow velocity (PAV; Figures 3B, 3C, and Table 1 ). These improved heart functions were similar to that of p110␥ single mutant hearts. These data show that the defect in cardiac contractility seen in the PTEN-deficient hearts is dependent on the PI3K␥ signaling pathway. Importantly, PTEN regulated hypertrophy can be genetically uncoupled from the cardiac contractility changes mediated by PTEN-PI3K␥.
Reversal of Cardiac Hypertrophy in PTEN-Deficient Hearts by a Dominant-Negative p110␣ Transgene
The increase in cell size found in PTEN-deficient hearts strongly resembles that seen in transgenic mice for heart specific constitutively active p110␣ that couples to receptor tyrosine kinases (Shioi et al., 2000) . Furthermore, mice transgenic for heart-specific dominant-negative p110␣ (DN-p110␣) have smaller than normal heart size. We therefore generated mice deficient for PTEN in the hearts and overexpressing the heart specific DN-p110␣ transgene. Hearts of mckCRE-PTEN ⌬/⌬ ;DN-p110␣ mice displayed a reduction in heart size similar to that seen in single DN-p110␣ transgenic mice ( Figures 4A and 4B) . The presence of the DN-p110␣ transgene also correlated with a decrease in the basal level of AKT/PKB activation in the absence or presence of a functional PTEN gene ( Figure 4C ). However, whereas overexpression of DN-p110␣ on a wild-type background affects heart size but has no apparent effect on heart function, hearts from mckCRE-PTEN ⌬/⌬ ;DN-p110␣ displayed a marked decrease in contractility ( Figures 4D, 4E , and Table 1 ). Taken together, these data show that PI3K␣ signaling modulates basal cell size of cardiomyocytes while PI3K␥ signaling controls basal cardiac contractility.
PI3K␥ and PTEN Control Contractility in Single Cells
To further analyze these in vivo contractility defects, we elucidated whether loss of PTEN and PI3K␥ can affect contractility of a single adult cardiomyocyte in vitro. In Table 1 hemodynamic data, it was found that PTEN deficient relaxation in p110␥ deficient cardiomyocytes compared to control cells despite a marked increase in peak concardiomyocytes display a reduction in contractility as determined by a reduction in percent cell shortening traction (Table 2 ). Cardiac relaxation is modulated via cAMP dependent pathways, where cAMP activates and positive and negative dL/dTs as compared to wildtype cardiomycoytes (Figures 5A and 5B; Table 2 ). Con-PKA, which then inhibits phospholamban (PLB) leading to increased sarcaplasmic reticulum calcium ATPase versely, p110␥ deficient myocytes displayed an increase in contractility (Figures 5A and 5B; Table 2 ). Cardiomyo-(SERCA) activity (Brittsan and Kranias, 2000). Moreover, it has previously been shown in vascular smooth muscle cytes deficient for both PTEN and p110␥ display increased contractility despite the hypertrophy present cells that pharmacological inhibition of PI3K can lead in these cells (Figures 5A and 5B; Table 2 ). Moreover, to increases in cAMP levels (Komalavilas et al., 2001 ). treatment of wild-type myocytes with the PI3K inhibitor To determine if alterations in cAMP levels may also be LY294002 lead to a significant increase in cardiomyocontributing to the phenotype observed here, we meacyte contractility. In p110␥ deficient cardiomyocytes, sured baseline cAMP levels in isolated myocytes. In addition of LY294002 had no effect on the already inunstimulated PTEN-deficient cardiomyocytes, cAMP creased contractility ( Figure 5B ; Table 2 ). These in vitro levels were significantly reduced ( Figure 5C ). Condata show that independent of exogenous agonists versely, an increase in cAMP levels was detected in PTEN and PI3K␥ control basal cardiomyocyte contractilisolated cardiomyocytes deficient for p110␥ ( Figure 5C ). ity within a single cell.
Importantly, treatment of PTEN-deficient and wild-type cardiomyocytes with the PI3K inhibitor Wortmannin resulted in a marked increase of cAMP to levels observed PI3K␥ Modulates Baseline cAMP Levels in Cardiomyocytes in p110␥ deficient cells ( Figure 5C ). Induction of cAMP production in response to the adenylate cyclase agonist One intriguing aspect of the in vitro contractility data is that there was a significant increase in the rate of forskolin was comparable among all genotypes ana- lyzed ( Figure 5D ) indicating that the basal machinery for activation of downstream targets using Rp-cAMP. In wild-type adult mouse cardiomyocytes, treatment with cAMP production is operational in all genotypes. These genetic data show that PI3K␥ and PTEN modulate cAMP Rp-cAMP lead to a marked decrease in contractility ( Figure 5E ; Table 2 ). Importantly, treatment of p110␥ production in cardiomyocytes.
To determine if these alterations in cAMP levels condeficient cardiomyocytes with the cAMP blocker lead to a greater reduction in contractility as compared to tribute to altered contractility, we measured contractility in single cells following blockade of cAMP-dependent wild-type cells such that the difference in the resultant (Table 2 ). These data indicate that alterations in baseline can modulate cAMP production following GPCR stimucAMP levels contribute to the increased contractility in lation, we purified neonatal cardiomyocytes from both p110␥ Ϫ/Ϫ hearts. wild-type and p110␥ Ϫ/Ϫ hearts and stimulated these cells with the ␤2-AR selective agonist zinterol. As described previously for adult rat myocytes (Kuznetsov et PI3K␥ and ␤-Adrenergic Signaling al., 1995), stimulation of the ␤2-AR had no affect on It has been previously shown that PI3K␥ can bind to cAMP levels in wild-type mouse cardiomyoctes. By con-GPCR-kinase 2 (GRK2; Naga Prasad et al., 2001a), a trast, selective stimulation of the ␤2-AR in p110␥
kinase that mediates desensitization of GPCRs like cardiomyocytes resulted in a marked increase in cAMP ␤-adrenergic receptors (␤-AR; Lefkowitz, 1998). Thus, levels ( Figure 6C ). Conversely, stimulation of ␤1-AR rewe speculated that ␤-adrenergic signaling may be afceptors resulted in a similar increase in cAMP levels fected in p110␥ Ϫ/Ϫ hearts, and that alterations of PI3K in both wild-type and p110␥-deficient cardiomyocytes activity may affect GRK activity and/or ␤-AR expression.
demonstrating selectivity for the action of PI3K␥ on Using an in vitro kinase assay, GRK activity in both cAMP production ( Figure 6D ). cytosolic and membrane-associated fractions of In cardiomyocytes, increased cAMP levels result in PTEN-deficient hearts was comparable to that of control enhanced contractility via activation of PKA and subsehearts ( Figure 6A ). Total protein levels of GRK2 were quent phosphorylation of phospholamban (PLB) in the also comparable ( Figure 6A ). Radiolabeled ligand bindsarcoplasmic reticulum (Brittsan and Kranias, 2000). ing assays showed that there is also no detectable differSimilar to cAMP production, no alteration of PLB phosence in the density of ␤-AR receptors or their affinity phorylation could be detected in wild-type cells upon for the ␤-AR ligand ICYP in the PTEN-or p110␥-deficient stimulation with the ␤2-AR agonist zinterol ( Figure 6E ). hearts as compared to wild-type mice ( Figure 6B ). These However, when p110␥ Ϫ/Ϫ cardiomyocytes were stimudata imply that changes in contractility of PTEN and lated with the same ␤2-AR agonist, a dose dependent p110␥-deficient hearts are not due to alterations in baseincrease in PLB phosphorylation was observed. Thus, line ␤-adrenergic receptor levels or the modulation of GRK activity.
in addition to its role in baseline cardiac contractility, loss of p110␥ expression releases the inhibition of the plays an important role in the regulation of basal cardiomyocyte size in vivo. ␤2-AR thereby permitting receptor-induced cAMP production and subsequent PLB-phosphorylation.
Our results show that PI3K␥ has no role in the homeostatic control of cardiomyocyte cell size. Yet many agonists used to induce PI3K-dependent cardiomyocyte Discussion hypertrophy in vitro are GPCR agonists (Rabkin et al., 1997; Schluter et al., 1999). Moreover, PI3K␥ is activated We elucidated the roles of PI3K-PTEN signaling in carin pressure overload induced hypertrophy in vivo (Naga diac hypertrophy and heart functions in PTEN-heart Prasad et al., 2000), implying a role for PI3K␥ in agonistmuscle specific mutant mice, p110␥ knockout, domiinduced cardiac hypertrophy. Thus, it will be interesting nant-negative p110␣ transgenic mice, and double-muto determine if PI3K␥ may play a role in agonist-induced tant mice. We show that the tyrosine kinase-receptor hypertrophy in vivo following stimulation of GPCRs. p110␣-PTEN pathway is a critical regulator of cardiac cell size. Intriguingly, our data revealed that the Regulation of Heart Muscle Contractility PTEN-PI3K␥ signaling pathway regulates heart muscle by PI3K␥ and PTEN contractility via GPCRs. This contractility phenotype is While the cardiac hypertrophy observed in the PTEN present in single cardiomyocytes and dependent on deficient hearts was similar to that seen in p110␣ transcAMP signaling. PI3K␥ regulates cardiac function by genic mice, PTEN deficient hearts surprisingly also disnegatively regulating cAMP levels and phospholamban played a dramatic decrease in cardiac contractility. Conphosphorylation upon ␤ 2 -adrenergic receptor stimulaversely, PI3K␥ deficient hearts exhibited an increase in tion. These data show that the tumor suppressor PTEN cardiac contractility. These data reveal that PI3K␥-PTEN has an important in vivo role in GPCR signaling and that signaling control heart muscle function in vivo. Impor-PTEN and PI3K␥ signaling control heart function.
tantly, the data presented here show that PI3K␥ can modulate contractility in the absence of exogenous agonists. These contractility changes are at least in part PTEN and Heart Muscle Size The cardiac hypertrophy in PTEN deficient hearts is simimediated by alteration in cAMP levels. An interesting conceptual issue arises from this work: lar to that in mice overexpressing a constitutively active p110␣ transgene in the heart ( ity in heart diseases. Moreover, inhibition of PI3K␥ may lead to better cardiac contractility in heart failure. 
